上海市第一人民医院
Shanghai General Hospital
在本站收录的 53 种疾病中,这家医院列在其中 20 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
上海市第一人民医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma5 篇牵头论文
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma3 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma36 篇牵头论文牵头 1 项开放试验
- 胃癌Stomach cancer27 篇牵头论文牵头 1 项开放试验
- 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
- 脊索瘤Chordoma5 篇牵头论文
- 骨肉瘤Osteosarcoma24 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour2 篇牵头论文
- 神经母细胞瘤Neuroblastoma0 篇牵头论文
- 多发性骨髓瘤Multiple myeloma2 篇牵头论文
- B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia0 篇牵头论文
- 再生障碍性贫血Aplastic anaemia0 篇牵头论文
- 血友病 AHaemophilia A0 篇牵头论文
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis1 篇牵头论文
- 大动脉炎Takayasu arteritis1 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
- IgA 肾病IgA nephropathy0 篇牵头论文
- 原发性硬化性胆管炎Primary sclerosing cholangitis0 篇牵头论文
- Leber 遗传性视神经病变Leber hereditary optic neuropathy2 篇牵头论文
未列出的收录疾病:肝母细胞瘤、尤文肉瘤、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 10 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。
这些数字背后的记录
牵头的论文5
- Combination of pan-immune-inflammation value and frailty index predicts the outcomes of elderly nasopharyngeal carcinoma treated by concurrent chemoradiotherapy.
- PICK1 inhibits the malignancy of nasopharyngeal carcinoma and serves as a novel prognostic marker.
- Identification of shared immune infiltration characteristic molecules in dermatomyositis and nasopharyngeal carcinoma using bioinformatics: Traits in dermatomyositis and nasopharyngeal cancer.
- Hypoxia-induced degradation of PICK1 by RBCK1 promotes the proliferation of nasopharyngeal carcinoma cells.
- Prognostic significance of MRI-based late-course tumor volume in locoregionally advanced nasopharyngeal carcinoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
PubMed 以外找到的论文(未计入)2
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
上海有 18 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
- 分期
- II期
- 开始
- 2024-02
- 登记号
- NCT06304350
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文3
- Copy number amplification of TTPAL promotes cholesterol biosynthesis and esophageal squamous cell carcinoma progression via elevating NSUN2-mediated m5C modification of SREBP2 mRNA.
- The mechanism of lovastatin in suppressing the proliferation of esophageal squamous cell carcinoma based on proteomics.
- CSMD1 suppresses cancer progression by inhibiting proliferation, epithelial-mesenchymal transition, chemotherapy-resistance and inducing immunosuppression in esophageal squamous cell carcinoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
- Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 36 篇,占 0.2%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 15 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma
- 分期
- 早期I期
- 开始
- 2024-11
- 登记号
- NCT06652243
年龄 18 岁 至 70 岁(登记的条件)
牵头:上海市第一人民医院上海
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文36
- A novel prognostic framework for HBV-infected hepatocellular carcinoma: insights from ferroptosis and iron metabolism proteomics.
- Exosome-derived SLC12A2-DT promotes macrophage M2 polarization-mediated hepatocellular carcinoma progression.
- vtRNA1-1 drives regorafenib resistance by sustaining cancer stemness via impaired autophagy and altered svRNA biogenesis.
- CCR8 antagonist suppresses liver cancer progression via turning tumor-infiltrating Tregs into less immunosuppressive phenotype.
- Circ_0098823 binding with IGF2BP3 regulates DNM1L stability to promote metastasis of hepatocellular carcinoma via mitochondrial fission.
- Bilateral diffuse uveal melanocytic proliferation secondary to combined hepatocellular-cholangiocarcinoma.
- 99mTc-Labeled D-Type PTP as a Plectin-Targeting Single-Photon Emission Computed Tomography Probe for Hepatocellular Carcinoma Imaging.
- Influence of recipient KRAS gene rs712 polymorphisms on the overall survival rate of hepatocellular carcinoma after hepatic transplantation.
- Inhibition of RhoGEF/RhoA alleviates regorafenib resistance and cancer stemness via Hippo signaling pathway in hepatocellular carcinoma.
- THAP3 recruits SMYD3 to OXPHOS genes and epigenetically promotes mitochondrial respiration in hepatocellular carcinoma.
- Multi-omics analysis reveals mechanism of Schisandra chinensis lignans and acteoside on EMT in hepatoma cells via ERK1/2 pathway.
- Endoscopic ultrasound for the diagnosis and treatment of primary hepatocellular carcinoma.
- Exploration of YBX1 role in the prognostic value and immune characteristics by single-cell and bulk sequencing analysis for liver hepatocellular carcinoma.
- HCC: RNA-Sequencing in Cirrhosis.
- Cuproptosis-related molecular patterns and gene (ATP7A) in hepatocellular carcinoma and their relationships with tumor immune microenvironment and clinical features.
- A model incorporating clinicopathologic and liver imaging reporting and data system-based magnetic resonance imaging features to identify hepatocellular carcinoma in LR-M observations.
- CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.
- Construction of a m5C-related long non-coding RNA signature for the prognosis of hepatocellular carcinoma.
- Characterization of the Clinical Significance and Immunological Landscapes of a Novel TMEMs Signature in Hepatocellular Carcinoma and the Contribution of TMEM201 to Hepatocarcinogenesis.
- Baseline ALBI Grade Predicts Benefits After Splenectomy for Cirrhotic Patients with Hypersplenism.
- Lysophosphatidylcholine acyltransferase 1 promotes epithelial-mesenchymal transition of hepatocellular carcinoma via the Wnt/β-catenin signaling pathway.
- SLC38A6, regulated by EP300-mediated modifications of H3K27ac, promotes cell proliferation, glutamine metabolism and mitochondrial respiration in hepatocellular carcinoma.
- Influences of Oral Administration of Probiotics on Posthepatectomy Recovery in Patients in Child-Pugh Grade.
- Combined analysis of imaging tumor capsule with imaging tumor size guides the width of resection margin for solitary hepatocellular carcinoma.
- The oncogenic miR-27a/BTG2 axis promotes obesity-associated hepatocellular carcinoma by mediating mitochondrial dysfunction.
- Clinical application of deep learning and radiomics in hepatic disease imaging: a systematic scoping review.
- Low expression of KIF20A suppresses cell proliferation, promotes chemosensitivity and is associated with better prognosis in HCC.
- Tumor suppressor DCAF15 inhibits epithelial-mesenchymal transition by targeting ZEB1 for proteasomal degradation in hepatocellular carcinoma.
- Estradiol is significantly associated with prognosis in non-surgical liver cancer patients: from bench to bedside.
- Recipient C7 rs9292795 genotype and the risk of hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population.
- Autophagy, an accomplice or antagonist of drug resistance in HCC?
- USP39 promotes tumorigenesis by stabilizing and deubiquitinating SP1 protein in hepatocellular carcinoma.
- Potential therapeutic targets in the tumor microenvironment of hepatocellular carcinoma: reversing the protumor effect of tumor-associated macrophages.
- Linc-SCRG1 accelerates progression of hepatocellular carcinoma as a ceRNA of miR26a to derepress SKP2.
- Reciprocal REGγ-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma.
- The role of daurisoline treatment in hepatocellular carcinoma: Inhibiting vasculogenic mimicry formation and enhancing sensitivity to sorafenib.
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma
- Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation
- Liver Transplantation Results in Hepatocellular Carcinoma Patients With Immunosuppression Without Steroids
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 27 篇,占 0.3%。
上海有 18 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
- 分期
- II期
- 开始
- 2022-09
- 登记号
- NCT05536102
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海市第一人民医院上海
- 正在招募Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- 分期
- III期
- 开始
- 2026-04
- 登记号
- NCT07385703
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛
- 正在招募Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- 分期
- III期
- 开始
- 2026-12
- 登记号
- NCT07789184
年龄 18 岁 至 70 岁(登记的条件)
牵头方不是列出的医院;另有 25 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、大连、天津、广州、杭州、武汉、济南、西安、重庆、长春、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文27
- Hypoxia-Induced circPRELID2 Promotes Gastric Cancer Metastasis by Facilitating ZEB2 Translation via PCBP1 O-GlcNAcylation.
- USP47 enhances NRP1-mediated angiogenesis to promote gastric cancer progression.
- FTO-Mediated m6A Demethylation of CCL2 Promotes Gastric Cancer Progression via Autophagy and Oxidative Stress Regulation.
- Exploration of the pharmacological substance basis and efficacy evaluation of fufang she-she-cao (Hedyotis diffusa formula) in repressing gastric cancer.
- A comprehensive study on the radiomic score derived from perineural invasion in gastric cancer and its correlation with the overall survival of patients.
- Insights into the role of glycosyltransferase in the targeted treatment of gastric cancer.
- Regulation of regulatory T cells and tumor-associated macrophages in gastric cancer tumor microenvironment.
- A deep learning model based on magnifying endoscopy with narrow-band imaging to evaluate intestinal metaplasia grading and OLGIM staging: A multicenter study.
- A predictive nomogram developed and validated for gastric cancer patients with triple-negative tumor markers.
- The role of microbiota in gastric cancer: A comprehensive review.
- DNA methyltransferase 3a-induced hypermethylation of the fructose-1,6-bisphosphatase-2 promoter contributes to gastric carcinogenesis.
- Five EMT-related genes signature predicts overall survival and immune environment in microsatellite instability-high gastric cancer.
- TCL1A acts as a tumour suppressor by modulating gastric cancer autophagy via miR-181a-5p-TCL1A-Akt/mTOR-c-MYC loop.
- Novel KDM2B/SAV1 Signaling Pathway Promotes the Progression of Gastric Cancer.
- Lactylation of METTL16 promotes cuproptosis via m6A-modification on FDX1 mRNA in gastric cancer.
- The features of gastric epithelial reactive hyperplastic lesions under magnifying endoscopy combined with narrow-band imaging.
- The kinase activity of integrin-linked kinase regulates cellular senescence in gastric cancer.
- Proteasome Subunit Alpha Type 7 Promotes Proliferation and Metastasis of Gastric Cancer Through MAPK Signaling Pathway.
- Endoscopic extraction of a gastric submucosal foreign body after precise location with endoscopic ultrasound combined with endoscopic submucosal dissection.
- Complete loss of miR-200 family induces EMT associated cellular senescence in gastric cancer.
- Progress and application of epitranscriptomic m6A modification in gastric cancer.
- High tumor mutation burden in a patient with metastatic gastric cancer sensitive to trastuzumab: a case report.
- The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer.
- ITIH4 is a novel serum biomarker for early gastric cancer diagnosis.
- MEF2A-mediated lncRNA HCP5 Inhibits Gastric Cancer Progression via MiR-106b-5p/p21 Axis.
- HOXA10 mediates epithelial-mesenchymal transition to promote gastric cancer metastasis partly via modulation of TGFB2/Smad/METTL3 signaling axis.
- Plexiform fibromyxoma: a clinicopathological and immunohistochemical analysis of two cases with a literature review.
它在 ClinicalTrials.gov 上的全部试验(任何状态)16
- The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
- Docetaxel-based Chemoradiotherapy Plus Periradiation Chemotherapy Compared With INT 0116 Adjuvant Arm in Gastric Cancer
- Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
- Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer
- Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
- Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
- Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
- A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 11 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
癌症
脊索瘤
Chordoma2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 4.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 15 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文5
- RAB3B Dictates mTORC1/S6 Signaling in Chordoma and Predicts Response to mTORC1-Targeted Therapy.
- Protocol for constructing in vivo and in vitro models integrating clinical and proteomic subtypes of chordoma.
- Clinical-proteomic classification and precision treatment strategy of chordoma.
- A comparative integrated multi-omics analysis identifies CA2 as a novel target for chordoma.
- Novel Nomograms as Aids for Predicting Recurrence and Survival in Chordoma Patients: A Retrospective Multicenter Study in mainland China.
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 24 篇,占 1.1%。
- 牵头的开放试验
- 0
- 正在或即将招募
上海有 60 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
- 分期
- II期
- 开始
- 2023-06
- 登记号
- NCT05830123
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、广州、杭州、郑州、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文24
- Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma.
- Prediction of Patients With High-Risk Osteosarcoma on the Basis of XGBoost Algorithm Using Transcriptome and Methylation Data From SGH-OS Cohort.
- Etoposide activates CD8+ T cell anti-tumor immunity in osteosarcoma through MHC I upregulation via tumor-secreted IL-33 mediated signaling.
- Enhanced Osteosarcoma Immunotherapy via CaCO3 Nanoparticles: Remodeling Tumor Acidic and Immune Microenvironment for Photodynamic Therapy.
- Engineering Bimetallic Polyphenol for Mild Photothermal Osteosarcoma Therapy and Immune Microenvironment Remodeling by Activating Pyroptosis and cGAS-STING Pathway.
- KDELR1 regulates chondrosarcoma drug resistance and malignant behavior through Intergrin-Hippo-YAP1 axis.
- Disrupting YAP1-mediated glutamine metabolism induces synthetic lethality alongside ODC1 inhibition in osteosarcoma.
- Eurycomanone inhibits osteosarcoma growth and metastasis by suppressing GRP78 expression.
- Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the JAK2/STAT3 signaling pathway.
- Lotus Seedpod-Inspired Crosslinking-Assembled Hydrogels Based on Gold Nanoclusters for Synergistic Osteosarcoma Multimode Imaging and Therapy.
- Pectolinarigenin acts as a potential anti-osteosarcoma agent via mediating SHP-1/JAK2/STAT3 signaling.
- Detection and surveillance of circulating tumor cells in osteosarcoma for predicting therapy response and prognosis.
- Feasibility and preliminary efficacy of tantalum components in the management of acetabular reconstruction following periacetabular oncologic resection in primary malignancies.
- Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications.
- Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment.
- CDK7/GRP78 signaling axis contributes to tumor growth and metastasis in osteosarcoma.
- Correlation between Patient-Derived Xenograft Modeling and Prognosis in Osteosarcoma.
- Revision surgeries for tumor endoprostheses around the knee joint: a mid-long-term follow-up of 20 cases.
- Identification of a novel glycolysis-related gene signature for predicting the prognosis of osteosarcoma patients.
- Her4 promotes cancer metabolic reprogramming via the c-Myc-dependent signaling axis.
- Osteosarcoma-derived exosomal miR-501-3p promotes osteoclastogenesis and aggravates bone loss.
- Identification of two immune subtypes in osteosarcoma based on immune gene sets.
- The disulfiram/copper complex induces apoptosis and inhibits tumour growth in human osteosarcoma by activating the ROS/JNK signalling pathway.
- MYLK4 promotes tumor progression through the activation of epidermal growth factor receptor signaling in osteosarcoma.
早期论文(2016–2020 年)28
- Costunolide inhibits osteosarcoma growth and metastasis via suppressing STAT3 signal pathway.
- circ_ARF3 regulates the pathogenesis of osteosarcoma by sponging miR-1299 to maintain CDK6 expression.
- Conditioned medium of the osteosarcoma cell line U2OS induces hBMSCs to exhibit characteristics of carcinoma-associated fibroblasts via activation of IL-6/STAT3 signalling.
- Local delivery of sunitinib and Ce6 via redox-responsive zwitterionic hydrogels effectively prevents osteosarcoma recurrence.
- Reduction-responsive polypeptide nanomedicines significantly inhibit progression of orthotopic osteosarcoma.
- Glaucocalyxin A-induced oxidative stress inhibits the activation of STAT3 signaling pathway and suppresses osteosarcoma progression in vitro and in vivo.
- Hydroxyurea promotes TET1 expression and induces apoptosis in osteosarcoma cells.
- Antitumor activity of Raddeanin A is mediated by Jun amino-terminal kinase activation and signal transducer and activator of transcription 3 inhibition in human osteosarcoma.
- Attenuation of STAT3 Phosphorylation Promotes Apoptosis and Chemosensitivity in Human Osteosarcoma Induced by Raddeanin A.
- Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
- Drug resistance-related microRNAs in osteosarcoma: Translating basic evidence into therapeutic strategies.
- CYT997(Lexibulin) induces apoptosis and autophagy through the activation of mutually reinforced ER stress and ROS in osteosarcoma.
- HER4 promotes cell survival and chemoresistance in osteosarcoma via interaction with NDRG1.
- Long non-coding RNA SNHG1 regulates NOB1 expression by sponging miR-326 and promotes tumorigenesis in osteosarcoma.
- Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells.
- Mesenchymal stem cells in the osteosarcoma microenvironment: their biological properties, influence on tumor growth, and therapeutic implications.
- Sarcoma-Targeting Peptide-Decorated Polypeptide Nanogel Intracellularly Delivers Shikonin for Upregulated Osteosarcoma Necroptosis and Diminished Pulmonary Metastasis.
- NDRG1 inhibition sensitizes osteosarcoma cells to combretastatin A-4 through targeting autophagy.
- Arsenic sulfide induces apoptosis and autophagy through the activation of ROS/JNK and suppression of Akt/mTOR signaling pathways in osteosarcoma.
- Alternol, a natural compound, exerts an anti-tumour effect on osteosarcoma by modulating of STAT3 and ROS/MAPK signalling pathways.
- Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3.
- Long non-coding RNAs in osteosarcoma.
- [Effect of rapamycin and chloroquine on osteosarcoma].
- MiR-326 is a diagnostic biomarker and regulates cell survival and apoptosis by targeting Bcl-2 in osteosarcoma.
- Erianin induces G2/M-phase arrest, apoptosis, and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells in vitro and in vivo.
- Bioinformatics analysis of differentially expressed pathways related to the metastatic characteristics of osteosarcoma.
- CD151-mediated adhesion is crucial to osteosarcoma pulmonary metastasis.
- Gelsolin promotes cell growth and invasion through the upregulation of p-AKT and p-P38 pathway in osteosarcoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
- Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors
- ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
- Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas
- Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma
- Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 21 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
这些数字背后的记录
牵头的论文2
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年没有牵头神经母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 34 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
这些数字背后的记录
早期论文(2016–2020 年)1
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.1%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 16 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
血液疾病
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia2021–2025 年没有牵头B 细胞急性淋巴细胞白血病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 9 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的B 细胞急性淋巴细胞白血病开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
- Comparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALL
- Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor(CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
- Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
血液疾病
再生障碍性贫血
Aplastic anaemia2021–2025 年没有牵头再生障碍性贫血的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 3 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
血液疾病
血友病 A
Haemophilia A2021–2025 年没有牵头血友病 A的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 9 家医院列在血友病 A下全国有 160 家医院列在血友病 A下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 9 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 8 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 34 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 17 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 26 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年没有牵头原发性硬化性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 13 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。
其他疾病
Leber 遗传性视神经病变
Leber hereditary optic neuropathy2021–2025 年中国大陆作者发表的 52 篇Leber 遗传性视神经病变 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 3 家医院列在Leber 遗传性视神经病变下全国有 32 家医院列在Leber 遗传性视神经病变下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。
联系这家医院
出示给工作人员或司机的院名卡
上海市第一人民医院
Shanghai General Hospital
上海
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR
Shanghai First People's Hospital; Jiading Branch of Shanghai General Hospital; Shanghai General Hospital Affiliated to Shanghai Jiaotong University; Shanghai General Hospital/Faculty of Basic Medicine; Shanghai General Hospital of Nanjing Medical University; Shanghai Jiaotong University Shanghai General Hospital; Shanghai General Hospital Affiliated to Nanjing Medical University; Jiading Branch of Shanghai First People's Hospital